pn 401 has been researched along with capecitabine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Traynor, K | 1 |
| Bai, G; Beaver, JA; Charlab, R; Chen, XH; Cheng, J; Dinin, J; Dorff, SE; Ibrahim, A; Ison, G; Jin, R; Kim, G; Liu, Q; Marathe, A; McGuinn, WD; McKee, AE; Palmby, TR; Pazdur, R; Pierce, W; Sridhara, R; Stephens, O; Tang, S; Wang, Y; Ysern, X | 1 |
| Bamat, MK; Cartwright, TH; El-Rayes, BF; Fakih, MG; King, TR; Ma, WW; Posey, JA; Saif, MW; von Borstel, RW | 1 |
| Wilkinson, E | 1 |
| Duffy, AP; Hausner, PF; Oliver, WD | 1 |
| Hu, EH; Keung, YK; Yu, D; Zurayk, M | 1 |
| Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D | 1 |
| Bamat, MK; Garcia, RAG; Saydoff, JA; von Borstel, RW | 1 |
| Brutcher, E; Christensen, D; Hennessey Smith, M; Koutlas, JB; Sellers, JB; Thompson, J; Timmons, T | 1 |
| Amylidi, AL; Angelaki, A; Aravantinos, G; Boumpoucheropoulos, S; Fildissis, G; Lampropoulou, DI; Laschos, K; Nanou, E; Nasioulas, G; Papadopoulou, E; Soupos, N; Zidianakis, V | 1 |
| Badea, A; Garcia, E; Gintjee, TJ; Goodnough, R; Li, K; Lynch, KL; Repplinger, D | 1 |
| Cantrell, FL; Friedman, NA; Galust, H; Hardin, J; Minns, A; Seltzer, JA | 1 |
5 review(s) available for pn 401 and capecitabine
| Article | Year |
|---|---|
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.
Topics: Acetates; Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Drug Approval; Drug Evaluation, Preclinical; Fluorouracil; Humans; Neoplasms; Prescription Drug Overuse; Research Design; Treatment Outcome; United States; United States Food and Drug Administration; Uridine | 2016 |
Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature.
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Middle Aged; Mutation; Uridine | 2019 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Humans; Neoplasms; Pyrimidines; Pyrrolidines; Quinazolines; Thiophenes; Thymine; Trifluridine; Uracil; Uridine | 2018 |
5-Fluorouracil and Capecitabine: Assessment and Treatment of Uncommon Early-Onset Severe Toxicities Associated With Administration.
Topics: Acetates; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Patient Safety; Risk Assessment; Severity of Illness Index; Survival Analysis; Uridine | 2018 |
Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Neoplasms; Uridine | 2020 |
7 other study(ies) available for pn 401 and capecitabine
| Article | Year |
|---|---|
FDA approves therapy to treat overdose of fluorouracil, capecitabine.
Topics: Acetates; Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemistry, Pharmaceutical; Drug Approval; Drug Overdose; Fluorouracil; Humans; United States; United States Food and Drug Administration; Uridine | 2016 |
Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Topics: Acetates; Antimetabolites, Antineoplastic; Capecitabine; Drug Overdose; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Uridine | 2017 |
An antidote to fluorouracil and capecitabine toxicity.
Topics: Acetates; Antidotes; Antineoplastic Agents; Capecitabine; Drug Costs; Drug Overdose; Fluorouracil; Humans; Treatment Outcome; Uridine | 2016 |
Case report of capecitabine toxicity and use of uridine triacetate.
Topics: Acetates; Aged; Antimetabolites, Antineoplastic; Capecitabine; Diarrhea; Drug Eruptions; Fatal Outcome; Humans; Liver Neoplasms; Male; Mucositis; Uridine | 2019 |
Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency.
Topics: Acetates; Animals; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Response Relationship, Drug; Drug Overdose; Female; Fluorouracil; Mice; Survival Analysis; Uridine | 2018 |
Real-time comprehensive toxicology testing in the clinical management of accidental pediatric capecitabine ingestion.
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Capecitabine; Child, Preschool; Humans; Male; Uridine | 2020 |
Oral Capecitabine Exposures and Use of Uridine Triacetate: A 20-Year Retrospective Analysis.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Genetic Predisposition to Disease; Humans; Middle Aged; Retrospective Studies | 2023 |